ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

Scientifically-designed fasting diet lowers risks for major diseases

How One Tiny Molecule Turned into One Huge Health Breakthrough

Acupuncture boosts effectiveness of standard medical care for chronic pain, depression

Research on Astaxanthin Demonstrates Significant Whole Body Benefits

Humans have three times more brown body fat

Nutrients Boost Stem Cell Function

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

Dietary prebiotics improve sleep, buffer impacts of stress, says study

 
Print Page
Email Article

New Alzheimer's Drug Offers Hope for Dementia

  [ 30 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 6, 2001



Scientific data presented at the seventeenth World Congress of Neurology show that the new Alzheimer’s drug, ReminylTM, is potentially effective in treating dementia in patients with cerebrovascular disease.

"This study has the potential to make a real impact on the way dementia is treated throughout the world," said Dr. Roger Bullock of the Kingshill Research Centre in Swindon, UK. "If the findings of this study are replicated through further research, physicians will no longer need to hesitate before treating dementia in individuals in whom vascular damage has occurred. Reminyl appears to be effective in treating dementia, whether or not cerebrovascular disease is present."

Reminyl improves memory, orientation, and language skills of patients with vascular dementia or a combination of Alzheimer's disease and cerebrovascular disease ("mixed" dementia) for at least 12 months.

The initial six-month, "double-blind" clinical study involved 592 patients diagnosed with vascular or mixed dementia, and received either 24mg per day of Reminyl (396) or placebo (196).
Of this group, 459 individuals (295 who had taken Reminyl and 164 who had previously received placebo) continued the research for another six months in an "open-label" extension of the study. All participants in the open-label extension took 24mg of Reminyl daily, in two divided doses.

At 12 months, the mental abilities of patients who had received Reminyl for the entire study period were better than when the individuals had commenced treatment.

The mental performance of patients who were originally assigned to take placebo had declined upon completion of the study's initial six months. However, after being switched to Reminyl, these patients' mental abilities improved; after the final six months, their performance was better than at the start of the study.

Over the course of the year, both groups of patients experienced deterioration in their ability to do tasks such as bathing, dressing and housework. However, the decline in the group receiving placebo for the first six months was more than double that of the group receiving Reminyl for the entire year.

In the study, Reminyl delayed emergence of hallucination, delusion, pacing and agitation symptoms in patients receiving active treatment for the entire study period, and alleviated such disturbances in individuals who were switched to Reminyl after six months' of placebo.

Reminyl is different from other Alzheimer's treatments that are currently available. In addition to inhibiting the breakdown of acetylcholine, a chemical in the brain critical to learning and memory, Reminyl has been shown in laboratory research to modulate "nicotinic receptors." It is believed that this results in the increased production of acetylcholine and other important chemicals in the brain.

In the overall study, Reminyl was generally well tolerated by patients. Most side effects were gastrointestinal in nature, of mild to moderate severity, and mainly confined to the period when the dose was being increased. Other research has shown that when the dose is increased at a slower rate, the occurrence of nausea and vomiting is not significantly greater than reported by patients taking placebo.

Results also showed that Reminyl improved or maintained the ability of these individuals to perform normal activities of daily living, such as bathing, dressing and doing housework. However, Reminyl is not yet approved for the treatment of vascular dementia.

Dementia is a decline in memory and intellectual abilities that results in a significantly impaired ability to function. The most common type of dementia is Alzheimer's disease. However, the second most common type is vascular dementia, which often is triggered by one or more strokes and can be caused by uncontrolled hypertension or diabetes.

World-wide incidence of vascular dementia is estimated at six to 12 cases per 1,000 people more than 70 years of age. Many other individuals have a mix of Alzheimer's and cerebrovascular disease. In fact, it is estimated that between 10 and 50 per cent of individuals have either vascular or mixed dementia. Unfortunately, these individuals are often unrecognized or untreated.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra ATP+, Double Strength Vitamin D3 Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10
Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map